Search
AZD-8848
go.drugbank.com/drugs/DB14868InvestigationalAZD-8848 is under investigation in clinical trial NCT01818869 (To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects).
GTX-758
go.drugbank.com/drugs/DB14969InvestigationalGTX-758 is under investigation in clinical trial NCT01420861 (GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer).
BMS-791826
go.drugbank.com/drugs/DB15023InvestigationalBMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).
TP-271
go.drugbank.com/drugs/DB15040InvestigationalTP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).
18-methoxycoronaridine
go.drugbank.com/drugs/DB15096Investigational18-methoxycoronaridine is under investigation in clinical trial NCT03084952 (Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients).
Tomuzotuximab
go.drugbank.com/drugs/DB15178InvestigationalTomuzotuximab is under investigation in clinical trial NCT02052960 (CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer).
Naratuximab emtansine
go.drugbank.com/drugs/DB15453InvestigationalNaratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).
BI 2536
go.drugbank.com/drugs/DB16107InvestigationalBI 2536 is under investigation in clinical trial NCT00376623 (Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer).
MOR-22
go.drugbank.com/drugs/DB17790ExperimentalMOR-22, a Natural human lymphoblastoid interferon-alpha, is currently being investigated to treat papillomavirus warts in the oral cavity of HIV-positive patients.
MM-111
go.drugbank.com/drugs/DB17983InvestigationalMM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.